DarioHealth (NASDAQ:DRIO) Stock Rating Lowered by TD Cowen

DarioHealth (NASDAQ:DRIO) was downgraded by research analysts at TD Cowen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, MarketBeat reports. They presently have a $1.00 price objective on the stock, down from their previous price objective of $2.00. TD Cowen’s target price points to a potential upside of 56.23% from the company’s current price.

DarioHealth Trading Down 2.3 %

NASDAQ DRIO opened at $0.64 on Wednesday. DarioHealth has a 12 month low of $0.56 and a 12 month high of $2.60. The company has a current ratio of 1.57, a quick ratio of 1.32 and a debt-to-equity ratio of 0.35. The stock has a 50 day moving average of $0.76 and a 200-day moving average of $0.90. The company has a market cap of $21.83 million, a PE ratio of -0.68 and a beta of 1.39.

DarioHealth (NASDAQ:DRIO) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The firm had revenue of $7.42 million during the quarter, compared to analyst estimates of $7.34 million. DarioHealth had a negative net margin of 205.62% and a negative return on equity of 72.16%. During the same quarter in the prior year, the business earned ($0.49) EPS. On average, equities research analysts anticipate that DarioHealth will post -1.18 EPS for the current fiscal year.

Institutional Trading of DarioHealth

A number of hedge funds have recently made changes to their positions in DRIO. DLK Investment Management LLC increased its holdings in shares of DarioHealth by 71.6% during the 3rd quarter. DLK Investment Management LLC now owns 100,550 shares of the company’s stock worth $113,000 after acquiring an additional 41,943 shares during the last quarter. Appian Way Asset Management LP boosted its position in DarioHealth by 2.5% during the third quarter. Appian Way Asset Management LP now owns 1,410,870 shares of the company’s stock worth $1,580,000 after purchasing an additional 34,990 shares during the period. Finally, XTX Topco Ltd increased its holdings in shares of DarioHealth by 81.4% in the third quarter. XTX Topco Ltd now owns 29,455 shares of the company’s stock valued at $33,000 after purchasing an additional 13,219 shares during the last quarter. 33.39% of the stock is owned by institutional investors and hedge funds.

DarioHealth Company Profile

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.